Description: Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company's products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism. The Company's products are under various clinical trials, including Chronocort, which is in Phase III clinical trial; Infacort, which is in Phase III clinical trial, and Native Oral Testosterone, which is in Phase I clinical trial.
Home Page: www.diurnal.co.uk
DNL Technical Analysis
Cardiff MediCentre
Cardiff,
CF14 4UJ
United Kingdom
Phone:
44 29 2068 2069
Officers
| Name | Title |
|---|---|
| Mr. Richard Edward Bungay A.C.A., ACA, B.Sc., BSc | Interim CEO, CFO, Company Sec. & Director |
| Prof. Richard Ross | Chief Scientific Officer & Exec. Director |
| Mr. Stewart Jones | Operations Director |
| Mr. John Porter MBBS, Ph.D. | Chief Medical Officer |
| Mr. David Bevan | Chief Bus. Officer |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2176 |
| Price-to-Sales TTM: | 10.1915 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |